Look back at pharma news in the week to January 8, 2021

10 January 2021

By Barbara Obstoj-Cardwell. Editor

As 2021 began, the first M&A deal of the year was announced, with Italy’s Angelini revealing the biggest acquisition in the company’s history, buying US CNS specialist Arvelle Therapeutics for up to $960 million. Also of note, Regeneron Pharmaceuticals announced positive initial data for its casirivimab plus imdevimab antibody cocktail in the treatment of hospitalized COVID-19 patients. US oncology focussed Calithera Biosciences released disappointing results for its lead candidate telaglenastat in renal cell carcinoma (RCC). Additionally, Alnylam Pharmaceuticals looks se for regulatory filings for its vutrisiran in the treatment of transthyretin-mediated ATTR amyloidosis following positive Phase III results.

Angelini seizes the initiative with Arvelle takeout

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK